Viola Zhu, MD, PhD of UC Irvine Health gives an overview of the ARCHER 1050 trial in EGFR+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract LBA9007: ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC at the First Line Setting
Advertisement